"6 choose 4": A framework to understand and facilitate discussion of strategies for overall survival safety monitoring
Fuente:
arXiv
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Preprint |
| Veröffentlicht: |
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866917128477605888 |
|---|---|
| author | Yung, Godwin Rufibach, Kaspar Wolbers, Marcel Yan, Mark Wang, Jue |
| author_facet | Yung, Godwin Rufibach, Kaspar Wolbers, Marcel Yan, Mark Wang, Jue |
| contents | Advances in anticancer therapies have significantly contributed to declining death rates in certain disease and clinical settings. However, they have also made it difficult to power a clinical trial in these settings with overall survival (OS) as the primary efficacy endpoint. Therefore, two approaches have been recently proposed for the pre-specified analysis of OS as a safety endpoint (Fleming et al., 2024; Rodriguez et al., 2024). In this paper, we provide a simple, unifying framework that includes the aforementioned approaches (and a couple others) as special cases. By highlighting each approach's focus, priority, tolerance for risk, and strengths or challenges for practical implementation, this framework can help to facilitate discussions between stakeholders on "fit-for-purpose OS data collection and assessment of harm" (American Association for Cancer Research, 2024). We apply this framework to a real clinical trial in large B-cell lymphoma to illustrate its application and value. Several recommendations and open questions are also raised. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2410_04020 |
| institution | arXiv |
| publishDate | 2024 |
| record_format | arxiv |
| spellingShingle | "6 choose 4": A framework to understand and facilitate discussion of strategies for overall survival safety monitoring Yung, Godwin Rufibach, Kaspar Wolbers, Marcel Yan, Mark Wang, Jue Methodology Applications Advances in anticancer therapies have significantly contributed to declining death rates in certain disease and clinical settings. However, they have also made it difficult to power a clinical trial in these settings with overall survival (OS) as the primary efficacy endpoint. Therefore, two approaches have been recently proposed for the pre-specified analysis of OS as a safety endpoint (Fleming et al., 2024; Rodriguez et al., 2024). In this paper, we provide a simple, unifying framework that includes the aforementioned approaches (and a couple others) as special cases. By highlighting each approach's focus, priority, tolerance for risk, and strengths or challenges for practical implementation, this framework can help to facilitate discussions between stakeholders on "fit-for-purpose OS data collection and assessment of harm" (American Association for Cancer Research, 2024). We apply this framework to a real clinical trial in large B-cell lymphoma to illustrate its application and value. Several recommendations and open questions are also raised. |
| title | "6 choose 4": A framework to understand and facilitate discussion of strategies for overall survival safety monitoring |
| topic | Methodology Applications |
| url | https://arxiv.org/abs/2410.04020 |